IMMUCELL CORP /DE/ 8-K

What Happened
ImmuCell Corporation (ICCC) announced on its Form 8-K (filed June 10, 2026) that its Board of Directors authorized a manufacturing capacity expansion to prioritize production of its flagship First Defense® colostrum products. The company suspended plans to make Re‑Tain® in‑house in late Dec 2025/Jan 2026 and will convert most related facilities and equipment to expand First Defense® production. The Board approval was dated June 4, 2026.

Key Details

• Board authorized a multi-phase capacity expansion program; Phase 1 begins immediately.
• Phase 1: renovate the former Re‑Tain® drying facility and add a new, higher‑capacity freeze dryer — expected to take ~12 months and cost approximately $3.5 million.
• Phase 2: repurpose Re‑Tain® equipment and add additional equipment and automation to expand and replace First Defense® colostrum processing capacity; will require additional investments and detailed engineering work.
• Disclosure provided under Regulation FD; statements are forward‑looking and subject to risks and uncertainties.

Why It Matters
This move signals ImmuCell is prioritizing capacity to meet expected demand for its First Defense® product line and is committing near‑term capital (about $3.5M for Phase 1) and time (~12 months) to increase production reliability. For investors, the announcement identifies a clear use of cash for capital expenditures rather than R&D or product diversification (Re‑Tain®), and it may affect near‑term production capability, operating costs, and future revenue potential if demand grows as expected. The filing does not include financial results or specific revenue guidance; the plan contains forward‑looking projections subject to change.